PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Prostate Cancer, Cancer, Blood Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 1/20/2019 |
| Start Date: | December 2010 |
| End Date: | December 2019 |
| Contact: | Mark Dunphy, DO |
| Phone: | 212-639-8131 |
The purpose of this study is to see how a new drug, named PUH71, accumulates in the different
parts of the body & inside tumors and how long PUH71 lasts in the blood, when given to study
participants in tiny amounts. The results of this study will help researchers (1) plan how
they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of
cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting
tumors with scanner machines.
parts of the body & inside tumors and how long PUH71 lasts in the blood, when given to study
participants in tiny amounts. The results of this study will help researchers (1) plan how
they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of
cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting
tumors with scanner machines.
Inclusion Criteria:
- Patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma
(histology confirmed by MSKCC Department of Pathology)
- Disease is measurable or evaluable as defined by RECIST (1.1 or original version) or
other tumor response criteria from an MSKCC IRB-approved clinical research protocol.
- This does not apply to patients with myeloproliferative neoplasm. The presence of
active myeloproliferative neoplasm will be determined by applicable disease specific
diagnostic criteria and patient assessment by the patient's oncologist and trial
investigators (eg, manifestations of active MPN such as splenomegaly, abnormal blood
counts, etc).
- Age between 18-90
- Negative serum pregnancy test for females of childbearing age (11-55 years) and/or
lack child-bearing potential
- No breast-feeding
Exclusion Criteria:
- Previous allergic reaction to contrast medium.
- Hypersensitivity to iodide products.
- Known hyperthyroidism
Hepatic:
- Bilirubin > 1.5 x institutional upper limit of normal (ULN)
- AST/ALT >2.5 x ULN
- Albumin < 2 g/dl
- GGT > 2.5 x ULN IF Alkaline phosphatase > 2.5 x ULN. Renal: Creatinine >1.5 x ULN or
creatinine clearance < 60 mL/min.
- Positive serum pregnancy test for females
- Acute major illness (e.g., infection, unstable cardiovascular condition, etc.)
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Mark Dunphy, DO
Phone: 212-639-8131
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
